Cardio Diagnostics Inc. (CDIO)
0.33
-0.05 (-13.11%)
At close: Mar 31, 2025, 3:34 PM
0.35
3.47%
After-hours: Mar 31, 2025, 07:44 PM EDT
-13.11% (1D)
| Bid | 0.29 |
| Market Cap | 17.44M |
| Revenue (ttm) | 74.43K |
| Net Income (ttm) | -17.88M |
| EPS (ttm) | -0.31 |
| PE Ratio (ttm) | -1.08 |
| Forward PE | -2.09 |
| Analyst | Hold |
| Ask | 0.41 |
| Volume | 1,943,660 |
| Avg. Volume (20D) | 2,346,932 |
| Open | 0.36 |
| Previous Close | 0.38 |
| Day's Range | 0.30 - 0.36 |
| 52-Week Range | 0.19 - 1.77 |
| Beta | 3.56 |
About CDIO
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois....
Industry Biotechnology
Sector Healthcare
IPO Date Jan 14, 2022
Employees 13
Stock Exchange NASDAQ
Ticker Symbol CDIO
Website https://cardiodiagnosticsinc.com
Analyst Forecast
According to 1 analyst ratings, the average rating for CDIO stock is "Hold." The 12-month stock price forecast is $2, which is an increase of 498.09% from the latest price.
Stock ForecastsNext Earnings Release
Cardio Diagnostics Inc. is scheduled to release its earnings on Apr 11, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · businesswire.com
Cardio Diagnostics Expands the Reach of its AI-Driven Precision Cardiovascular Medicine Tests by Partnering with Seven New Provider OrganizationsCHICAGO--(BUSINESS WIRE)--Cardio Diagnostics has announced that the Company has partnered with seven new provider organizations.